MeiraGTx Holdings plc
MGTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.3B
$13.89
▼ -0.57%
P/E
16.34
Mkt Cap
$1.3B
52-Wk Range
$6.62–$15.35
52-Week Range
$6.62 - $15.35
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 85.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary riboswitch technology enabling regulatable gene therapy with precise control over therapeutic protein expression
- Diversified clinical pipeline across multiple high-value therapeutic areas with limited competitive alternatives
- Strategic partnership with Janssen Pharmaceuticals providing development expertise and commercialization potential
Bear Case
2 risks
- Average volatility.
- Significant premium - growth priced in
Growth
Revenue decline expected
Advancement of Phase 1/2 clinical programs toward later-stage development and potential regulatory approvals
Value
Significant premium - growth priced in
Momentum
Hot
+52.8% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MGTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 13, 2026
Reported EPS of $1.71 vs -$0.46 consensus (+473.1% surprise). Revenue of $321.4M vs $700.0K expected (+45819.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+473.1%
Revenue trend · last 8Q
—
—
+949%
+176%
+1209%
-96%
+252%
+16589%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q2 26
$282.0K
$10.9M
$21.4M
$1.9M
$3.7M
$410.0K
$75.4M
$321.4M
Margins · last 8Q
Gross
99.6%
Operating
76.0%
Profit
50.0%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Jul 8, 2026
vs Industry
How MGTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related